178 related articles for article (PubMed ID: 28610984)
21. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C
J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834
[TBL] [Abstract][Full Text] [Related]
22. Improved synthesis of MC4-PPEA and the biological evaluation of its hydroxymethyl derivative.
Sadrerafi K; Zargham EO; Lee MW
Bioorg Med Chem Lett; 2016 Jan; 26(2):618-621. PubMed ID: 26681512
[TBL] [Abstract][Full Text] [Related]
23. Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
Ozgencil F; Eren G; Ozkan Y; Guntekin-Ergun S; Cetin-Atalay R
Bioorg Med Chem; 2020 Jan; 28(1):115217. PubMed ID: 31818629
[TBL] [Abstract][Full Text] [Related]
24. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Chen H; Wang S; Zhang H; Nice EC; Huang C
Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
[TBL] [Abstract][Full Text] [Related]
25. Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition.
Akiu M; Tsuji T; Sogawa Y; Terayama K; Yokoyama M; Tanaka J; Asano D; Sakurai K; Sergienko E; Sessions EH; Gardell SJ; Pinkerton AB; Nakamura T
Bioorg Med Chem Lett; 2021 Jul; 43():128048. PubMed ID: 33887438
[TBL] [Abstract][Full Text] [Related]
26. Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase.
Lu T; Chen F; Yao J; Bu Z; Kyani A; Liang B; Chen S; Zheng Y; Liang H; Neamati N; Liu Y
J Med Chem; 2024 May; 67(10):8099-8121. PubMed ID: 38722799
[TBL] [Abstract][Full Text] [Related]
27. Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
Travelli C; Aprile S; Mattoteia D; Colombo G; Clemente N; Scanziani E; Terrazzino S; Alisi MA; Polenzani L; Grosa G; Genazzani AA; Tron GC; Galli U
Eur J Med Chem; 2019 Nov; 181():111576. PubMed ID: 31400709
[TBL] [Abstract][Full Text] [Related]
28. Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
Travelli C; Aprile S; Rahimian R; Grolla AA; Rogati F; Bertolotti M; Malagnino F; di Paola R; Impellizzeri D; Fusco R; Mercalli V; Massarotti A; Stortini G; Terrazzino S; Del Grosso E; Fakhfouri G; Troiani MP; Alisi MA; Grosa G; Sorba G; Canonico PL; Orsomando G; Cuzzocrea S; Genazzani AA; Galli U; Tron GC
J Med Chem; 2017 Mar; 60(5):1768-1792. PubMed ID: 28165742
[TBL] [Abstract][Full Text] [Related]
29. Fragment-based discovery of a potent NAMPT inhibitor.
Korepanova A; Longenecker KL; Pratt SD; Panchal SC; Clark RF; Lake M; Gopalakrishnan SM; Raich D; Sun C; Petros AM
Bioorg Med Chem Lett; 2018 Feb; 28(3):437-440. PubMed ID: 29287958
[TBL] [Abstract][Full Text] [Related]
30. Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Giannetti AM; Zheng X; Skelton NJ; Wang W; Bravo BJ; Bair KW; Baumeister T; Cheng E; Crocker L; Feng Y; Gunzner-Toste J; Ho YC; Hua R; Liederer BM; Liu Y; Ma X; O'Brien T; Oeh J; Sampath D; Shen Y; Wang C; Wang L; Wu H; Xiao Y; Yuen PW; Zak M; Zhao G; Zhao Q; Dragovich PS
J Med Chem; 2014 Feb; 57(3):770-92. PubMed ID: 24405419
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening.
Takeuchi M; Niimi T; Masumoto M; Orita M; Yokota H; Yamamoto T
Biol Pharm Bull; 2014; 37(1):31-6. PubMed ID: 24389478
[TBL] [Abstract][Full Text] [Related]
32. Structural basis for resistance to diverse classes of NAMPT inhibitors.
Wang W; Elkins K; Oh A; Ho YC; Wu J; Li H; Xiao Y; Kwong M; Coons M; Brillantes B; Cheng E; Crocker L; Dragovich PS; Sampath D; Zheng X; Bair KW; O'Brien T; Belmont LD
PLoS One; 2014; 9(10):e109366. PubMed ID: 25285661
[TBL] [Abstract][Full Text] [Related]
33. Optimization of a urea-containing series of nicotinamide phosphoribosyltransferase (NAMPT) activators.
Pinkerton AB; Sessions EH; Hershberger P; Maloney PR; Peddibhotla S; Hopf M; Sergienko E; Ma CT; Smith LH; Jackson MR; Tanaka J; Tsuji T; Akiu M; Cohen SE; Nakamura T; Gardell SJ
Bioorg Med Chem Lett; 2021 Jun; 41():128007. PubMed ID: 33798699
[TBL] [Abstract][Full Text] [Related]
34. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.
Galli U; Travelli C; Massarotti A; Fakhfouri G; Rahimian R; Tron GC; Genazzani AA
J Med Chem; 2013 Aug; 56(16):6279-96. PubMed ID: 23679915
[TBL] [Abstract][Full Text] [Related]
35. Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
Zhang K; Ni Y; Chen J; Tu Z; Wu X; Chen D; Yao H; Jiang S
Bioorg Med Chem Lett; 2019 Jun; 29(12):1502-1506. PubMed ID: 30992165
[TBL] [Abstract][Full Text] [Related]
36. Nicotinamide phosphoribosyltransferase is a molecular target of potent anticancer agents identified from phenotype-based drug screening.
Yamaguchi D; Imaizumi T; Yagi K; Matsumoto Y; Nakashima T; Hirose A; Kashima N; Nosaka Y; Hamada T; Okawa K; Nishiya Y; Kubo K
Sci Rep; 2019 May; 9(1):7742. PubMed ID: 31123329
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel NAMPT inhibitors based on pharmacophore modeling and virtual screening techniques.
Yi Q; Zhou L; Shao X; Wang T; Bao G; Shi H; Zhou S; Li X; Tian Y
Comb Chem High Throughput Screen; 2014; 17(10):868-78. PubMed ID: 25413783
[TBL] [Abstract][Full Text] [Related]
38. Crystal structure-based comparison of two NAMPT inhibitors.
Zhang SL; Xu TY; Yang ZL; Han S; Zhao Q; Miao CY
Acta Pharmacol Sin; 2018 Feb; 39(2):294-301. PubMed ID: 28858298
[TBL] [Abstract][Full Text] [Related]
39. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
[TBL] [Abstract][Full Text] [Related]
40. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
Zhang RY; Qin Y; Lv XQ; Wang P; Xu TY; Zhang L; Miao CY
Anal Biochem; 2011 May; 412(1):18-25. PubMed ID: 21211508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
